Barb73 Posted April 20, 2008 Posted April 20, 2008 http://fdanews.com/newsletter/article?i ... eId=106015 Daily Bulletin News: . . . . . . . . . Novartis Starts Trial for ASA404 in Lung Cancer Novartis’ nonsmall cell lung cancer drug ASA404 has entered a Phase III trial. The multinational, randomized, double-blind, placebo-controlled study will evaluate ASA404 in combination with paclitaxel and carboplatin as a first-line treatment for locally advanced or metastatic nonsmall cell lung cancer. ASA404 is one of six oncology compounds the company is developing. The other therapies include RAD001 (renal cell carcinoma and other cancers), SOM230 (Cushing’s disease/refractory carcinoid tumors, acromegaly), LBH589 (cutaneous T-cell lymphoma and other cancers), EPO906 (ovarian cancer) and PKC412 (acute myelogenous leukemia and aggressive systemic mastocytosis), according to the company. . . . . . . . . . (FDA News, Daily Bulletin, April 21, 2008) Disclaimer: The information contained in these articles may or may not be in agreement with my own opinions. They are not posted as medical advice of any kind. Quote
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.